Adial Pharmaceuticals reports $52.0M Q2 net loss, cash $28.7M after $32M financing
I'm LongbridgeAI, I can summarize articles.Adial Pharmaceuticals reported a Q2 2026 net loss of $52.0 million, primarily due to a $46.2 million in-process R&D charge from acquiring Azora Therapeutics. The company raised an initial $32 million via private placement, bringing cash reserves to $28.7 million. Adial is shifting its strategic focus to ulcerative colitis with lead drug AT177, aiming for an IND filing in H1 2027.
Adial Pharmaceuticals reported a net loss of $52.0 million, or $(11.25) per share, for the quarter ended June 30, 2026, driven largely by a $46.2 million acquired in‑process R&D charge. The company closed an initial $32 million tranche of a private placement and had cash and cash equivalents of $28.7 million as of June 30, 2026. Management said the acquisition of Azora Therapeutics adds AT177 and shifts the company’s strategic focus to ulcerative colitis with an IND planned in H1 2027.
Financial Highlights
- Net loss: $52.0 million for Q2 2026, or $(11.25) per basic and diluted share (4,621,735 weighted-average shares).
- Acquired in‑process research and development expense: $46.2 million recorded in Q2 2026 (non-cash).
- General and administrative expenses: $5.4 million for Q2 2026, up from $1.2 million in Q2 2025.
- Research and development expenses: $440 thousand for Q2 2026, down from $732 thousand in Q2 2025.
- Cash and cash equivalents: $28.7 million as of June 30, 2026 (compared to $4.6 million as of March 31, 2026); company expects cash to fund operations into H2 2027 excluding potential additional tranche.
Business Highlights
- Completed acquisition of Azora Therapeutics, adding AT177, a fully synthetic oral colon‑targeted aryl hydrocarbon receptor (AhR) agonist for ulcerative colitis.
- Closed initial $32 million tranche of an up to $64 million private placement led by biotech institutional investors; included conversion of $5.5 million of notes.
- Shifted strategic focus from addiction treatments to inflammatory diseases, with lead program AT177 targeting localized colonic delivery to minimize systemic exposure.
- Reported progress across preclinical and CMC programs and remains on track to file an IND for AT177 in the first half of 2027, with a Phase 1a SAD/MAD trial planned for H2 2027 and a subsequent Phase 1b proof‑of‑concept in UC patients.
- Enhanced board and executive leadership with experienced pharmaceutical industry veterans to support small molecule drug development and clinical advancement.
Original SEC Filing: ADIAL PHARMACEUTICALS, INC. [ ADIL ] - 8-K - Aug. 17, 2026